NASDAQ · MASI

Masimo Corporation

Healthcare · Medical - Devices

$179.950.00% ($0.00)at close

As of 9:30 AM ET

52-week

$125.94$179.99

Market cap

$9.42B

P/E

What the market price implies · Reverse DCF

To support a price of $179.95, this model requires revenue to grow by 20.6%/yr over the next 10 years, compounded annually.

Historical revenue grew by 5.36%/yr over the past 4 years. The required annual growth rate is 15.24 percentage points higher.

Selected forecast · Base scenario

3.08%/yr · actual 10-year annualized revenue growth

Year 1 growth: 4.82%

Market-implied · Base operating assumptions + edited margins

20.6%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$179.95

Estimated value / share

$53.28

Base scenario

This estimate is 70.39% below the price used.

USD · TTM ending 2026-04-04

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth 4.82% · Ending margin 19.85% · Discount rate 11.11%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Jun 12, 2026, 1:30 PM UTC
Financial statement period: TTM ending 2026-04-04
Data refreshed: Sep 18, 2026, 2:30 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.

1Y Price: 8.84%Revenue (TTM): -14.42%FCF (TTM): 52.19%P/FCF: 35th pct

What changed

The stock rose 8.84% over the last year. Revenue declined 14.42% over the trailing twelve months. Operating margin moved from -11.48% to 19.85%. Free cash flow grew 52.19% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at 19.85%. A decisive move in revenue — currently down 14.42% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.

CEOCatherine Szyman

SectorHealthcare

IndustryMedical - Devices

Employees7,500

IPO dateAug 8, 2007

https://www.masimo.com

Market multiples

Forward P/E—

EV/EBITDA21.00

Enterprise value$7.24B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth8.49%

Gross margin (FY2025)61.9%▲13.9ppvs FY2024

Operating margin (FY2025)20.49%▲33.2ppvs FY2024

ROE8.79%▲25.9ppvs FY2025

Analyst consensus

RatingBuy

Target price$176.00▼2.20%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Aug 4, 2026

Q3 FY26 · EPS est $1.43 · Revenue est $398.5M

View